The global tuberculosis therapeutics market was valued at around US$ 1.1 Billion at the end of 2021. The market is projected to register a 7.1% CAGR and top a valuation of US$ 2.3 Billion by 2032.
The rising prevalence of tuberculosis, and the rising incidence of multi-drug resistant (MDR) and extensively drug-resistant tuberculosis (XDR) cases in developing countries are likely to encourage the tuberculosis therapeutics market growth.
An infectious disease called tuberculosis (TB) is typically brought on by the bacteria called Mycobacterium tuberculosis (MTB). Although TB often affects the lungs, other body parts are also susceptible to tuberculosis. Latent TB is the term used when an infection does not show any symptoms. 10% of latent infections develop into active disease, which, if untreated, kills around 50% of individuals who are infected. Blood with mucus in the cough, fever, nocturnal sweats, and loss of weight are all signs of active TB.
Isoniazid INH in combination with rifampin, pyrazinamide, and ethambutol is the most widely used treatment for active Tuberculosis.
| Attributes | Details |
|---|---|
| Tuberculosis Therapeutics Market Value in 2021 | US$ 1.1 Billion |
| Tuberculosis Therapeutics Market Value in 2032 | US$ 2.3 Billion |
| Tuberculosis Therapeutics Market CAGR (2022 to 2032) | 7.1% |
Tuberculosis is one of the top 10 causes of death worldwide. Leading medical regulatory authorities are challenged by the prevalence of tuberculosis around the world. It is anticipated that there would be an increase in tuberculosis diagnoses as a result of the government's and medical community's strong involvement in the prevention of this disease. Thus, this will expand the global tuberculosis therapeutics market.
The market for tuberculosis therapeutics is expected to grow as the elderly population increases. Due to their weakened immune systems, older individuals are more susceptible to both chronic and acute diseases. Due to the immune system-weakening effects of several medications, such as chemotherapy and those used to treat arthritis and psoriasis, tuberculosis risk is increased.
Additionally, the market for tuberculosis therapeutics will grow as a result of increased awareness-raising efforts by both governmental and private organizations. The market for tuberculosis therapeutics will also grow as a result of people's changing lifestyles, an increase in instances of MDR-TB and XDR-TB in developing nations, and changing consumer preferences.
North America holds the major chunk of the global tuberculosis therapeutics market. Due to the existence of well-established key players, growing cases of tuberculosis in the region, and increased healthcare spending.
Due to the presence of a large geriatric population suffering from chronic diseases, Europe is predicted to have the fastest-growing demand for tuberculosis therapeutics.
East Asia is expected to grow lucratively during the course of the forecast period as a result of the rising number of generic manufacturers, and expansion of healthcare infrastructure.
AstraZeneca PLC, Eli Lilly, and Company, GlaxoSmithKline PLC, Johnson & Johnson, Lupin Ltd., Merck & Co., Inc., Otsuka Pharmaceutical Co., Ltd., Panacea Biotec Ltd., Pfizer, Inc., Sanofi, Novartis AG, Sun Pharmaceuticals Industries Ltd.
| Report Attributes | Details |
|---|---|
| Growth Rate | CAGR of 7.1% from 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2012 to 2021 |
| Forecast Period | 2022 to 2032 |
| Qualitative Units | Revenue in USD Billion, and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends |
| Segment Covered | Disease Type, Treatment Type, Diagnosis, Dosage Form, End User, Region |
| Region Covered | North America; Latin America; Europe; East Asia; South Asia; Oceania; Middle East & Africa |
| Key Countries Profiled | USA, Canada, Brazil, Mexico, Germany, UK, France, Spain, Italy, China, Japan, South Korea, Malaysia, Singapore, Australia, New Zealand, GCC Countries, South Africa, Israel |
| Key Players | AstraZeneca PLC; Eli Lilly and Company; GlaxoSmithKline PLC; Johnson & Johnson; Lupin Ltd.; Merck & Co., Inc.; Otsuka Pharmaceutical Co., Ltd.; Panacea Biotec Ltd.; Pfizer, Inc.; Sanofi; Novartis AG; SunPharmaceuticals Industries Ltd. |
| Customization | Available Upon Request |
The global tuberculosis therapeutics market is anticipated to register a CAGR of 7.1% during the forecast period.
The top players in the global tuberculosis therapeutics market are AstraZeneca PLC, Eli Lilly and Company, GlaxoSmithKline PLC, Johnson & Johnson, Lupin Ltd., Merck & Co., Inc., Otsuka Pharmaceutical Co., Ltd., Panacea Biotec Ltd., Pfizer, Inc., Sanofi, Novartis AG, Sun Pharmaceuticals Industries Ltd.
Explore Similar Insights
Tuberculosis Therapeutics Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
